Hua Zheng

Dr. Hua Zheng is Senior Vice President & Head of Global Regulatory Affairs at AnHeart Therapeutics. He has more than 25 years of experience in regulatory strategy to advance global product development and registration. He has served in executive regulatory positions in a number of leadership roles (Vice President, Global Franchise Regulatory Lead, China Lead), and has held various positions at multi-national companies such as Pfizer, J&J, Celgene, Amgen and biotech companies Advaxis and Sorrento. He has also served at the U.S. FDA. He has led and directed regulatory activities across all phases of global drug development, including the US, China, Europe and Asia Pacific, in gaining approvals. Notably, he served in critical leadership roles leading to market registrations for Yondelis, Edurant, Revlimid, and Vidaza in different countries with diverse regulatory challenges. Dr. Zheng holds a Ph.D. in Toxicology from the University of California, Irvine. He has an M.Sc. in Pathology and completed his medical training at the former Beijing Medical University. He conducted postdoctoral research at the National Cancer Institute, Kansas University Medical Center and the University of California, San Diego.